Anti-GPIIIa49–66 scFv (A11) 8 days after removal of obstruction
| . | N . | Infarction, percentage . | P* . | Cavitation† . | P* . | Postural reflex‡ . | P* . | Rotor rod§ . | P* . | Traverse beam§ . | P* . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Post A11 | 9 | 24.8 ± 5.5 | .002 | 1.52 ± 1.0 | .01 | 0.41 ± 0.18 | < .001 | 4.98 ± 0.28 | .003 | 6.96 ± 0.037 | < .001 |
| Pre A11 | 9 | 25.5 ± 6.0 | < .001 | 4.64 ± 1.7 | < .001 | 0.82 ± 0.25 | < .001 | 3.94 ± 0.36 | .038 | 6.33 ± 0.39 | .049 |
| Saline | 14 | 43.0 ± 4.8 | — | 9.98 ± 1.9 | — | 2.31 ± 0.25 | — | 3.19 ± 0.34 | — | 4.52 ± 0.46 | — |
| Control scFv | 5 | 37.2 ± 6.2 | — | 8.80 ± 2.1 | — | 2.00 ± 0.39 | — | 3.33 ± 0.48 | — | 4.27 ± 0.61 | — |
| . | N . | Infarction, percentage . | P* . | Cavitation† . | P* . | Postural reflex‡ . | P* . | Rotor rod§ . | P* . | Traverse beam§ . | P* . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Post A11 | 9 | 24.8 ± 5.5 | .002 | 1.52 ± 1.0 | .01 | 0.41 ± 0.18 | < .001 | 4.98 ± 0.28 | .003 | 6.96 ± 0.037 | < .001 |
| Pre A11 | 9 | 25.5 ± 6.0 | < .001 | 4.64 ± 1.7 | < .001 | 0.82 ± 0.25 | < .001 | 3.94 ± 0.36 | .038 | 6.33 ± 0.39 | .049 |
| Saline | 14 | 43.0 ± 4.8 | — | 9.98 ± 1.9 | — | 2.31 ± 0.25 | — | 3.19 ± 0.34 | — | 4.52 ± 0.46 | — |
| Control scFv | 5 | 37.2 ± 6.2 | — | 8.80 ± 2.1 | — | 2.00 ± 0.39 | — | 3.33 ± 0.48 | — | 4.27 ± 0.61 | — |
Data are mean ± SEM.
— indicates not applicable.
Two-tailed t test comparison of saline vehicle versus intravenous injection of 25 μg of A11 Ab or control scFv given 2 hours before (Pre) or 2 hours after (Post) obstruction and release of right middle cerebral artery.
Cavitation refers to the formation of cavities in brain; a higher number reflects greater neurologic impairment.
With postural reflex, a higher number reflects a higher number of errors and greater neurologic impairment.
With rotor rod and traverse beam score, a higher number reflects greater neurologic impairment. No microscopic hemorrhage was seen.